Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
- 5 January 2025
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (6) , 959-970
Abstract
Objective: Primary liver cancer (PLC) is projected to be the third leading cause of cancer mortality in the United States in 2040. We examine the burden of PLC in the United States, stratified by sex, state and aetiological risk factors.Methods: Data on PLC prevalence, incidence, death and disability–adjusted life years (DALYs) were extracted from the Global Burden of Disease Study 2021. Changes in these parameters were calculated using the Joinpoint regression model.Results: There were 47,970 cases, 31,450 incident cases, 24,770 deaths and 576,920 DALYs from PLC in the United States. The highest prevalence (16,980), incidence (12,040), death (9840) and DALYs (213,410) from PLC were due to chronic hepatitis C virus infection. From 2000 to 2021, PLC incidences increased by 141%, and PLC deaths increased by 136%. Age–standardised incidence rates (ASIRs) and death rates (ASDRs) per 100,000 population for PLC increased, primarily driven by alcohol–related liver disease (ALD) (ASIR: annual percent change [APC]: +2.40%; ASDR: APC: +2.22%) and metabolic dysfunction–associated steatotic liver disease (MASLD) (ASIR: APC: +2.32%; ASDR: APC: +2.04%).Conclusion: The burden of PLC in the United States has risen in the past two decades, driven mainly by ALD and followed by MASLD. These findings offer policymakers an accurate assessment of the PLC burden and emphasise the need for targeted risk factor mitigation, especially regarding alcohol related policy.Keywords
Funding Information
- National Institutes of Health (K08CA259534, R01 CA256977)
This publication has 72 references indexed in Scilit:
- Decreasing incidence of hepatocellular carcinoma among most racial groups: SEER‐22, 2000–2019Cancer Medicine, 2023
- Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019International Journal of Cancer, 2023
- NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant CandidatesClinical Gastroenterology and Hepatology, 2023
- Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASHHepatology, 2022
- Health disparities in chronic liver diseaseHepatology, 2022
- PNPLA3 Gene Polymorphism and Liver- and Extrahepatic Cancer–Related Mortality in the United StatesClinical Gastroenterology and Hepatology, 2021
- Epidemiology of Hepatocellular CarcinomaHepatology, 2020
- Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐AnalysisHepatology, 2020
- Hepatitis B Treatment: What We Know Now and What Remains to Be ResearchedHepatology Communications, 2018
- Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysisCancer, 2014